The S100 calcium-binding protein beta subunit (S100B) protein, which mostly exists in the central nervous system, is commonly noted as a marker of neuronal damage. We conducted the first systematic review with meta-analysis to compare peripheral blood S100B levels in individuals with ASD with those in healthy controls. A systematic search was carried out for studies published before May 5, 2020. In total, this meta-analysis involved ten studies with 822 participants and 451 cases. The meta-analysis revealed that individuals with ASD had higher peripheral blood S100B levels than healthy controls [standardized mean difference (SMD) = 0.97, 95% confidence interval (95% CI) = 0.41–1.53; p < 0.001]. Peripheral blood S100B levels may have potential as a useful biomarker for ASD.
Opmerkingen
Zhen Zheng, Peng Zheng have contributed equally to this report.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Autism spectrum disorder (ASD) comprises neurodevelopmental disorders specified by stereotypic behaviour, limited social interaction, and impaired communication. The worldwide prevalence of ASD is approximately 1% (Baxter et al. 2015). A higher prevalence of one per 54 children aged 8 years was reported in the United States, and the male-to-female ratio was about 4.3:1 (Maenner et al. 2020). The prevalence of ASD has increased rapidly, while there is a lack of specific treatment for ASD. ASD starts early and lasts throughout the lifetime, which affects the quality of life for individuals with ASD and places a financial burden on families. Therefore, ASD is considered a major concern for public health worldwide.
However, the cause of ASD has not yet been identified. Current evidence suggests that ASD may be a genetically and environmentally determined disorder (Mandy and Lai 2016; Robinson et al. 2016). To date, there are no specific biomarkers for ASD, and the diagnosis must be based on behaviour. Abnormal behaviour is not obvious until about 12–18 months old. In addition, ASD is correlated with mental diseases such as anxiety and schizophrenia (Lai et al. 2019; Zheng et al. 2018) but is not correlated with medical diseases such as allergies and asthma (Lyall et al. 2015; Zheng et al. 2016a). This complexity has spurred a search for biomarkers that can provide early diagnosis and predict treatment response. Multiple studies have reported that biomarkers like glutamate and brain-derived neurotrophic factor can help diagnose ASD and Alzheimer’s disease early (Qin et al. 2017, 2016; Zheng et al. 2016b, c). However, there is still a need for specific biomarkers relevant only to ASD.
The S100 calcium-binding protein beta subunit (S100B) protein is commonly noted as a marker of neuronal damage and blood–brain barrier dysfunction (Koh and Lee 2014). The S100B protein mainly exists in the Schwann cells and glial cells of the central nervous system. The S100B protein plays important roles in neuronal survival, differentiation, apoptosis, astrocytic proliferation and the regulation of neuroinflammation (Michetti et al. 2019). Evidence suggested that following inflammation and stress, neurons were damaged and blood–brain barrier was dysfunction. S100B may release from the damaged neurons into the bloodstream, and its concentration in the peripheral blood is increased (Michetti et al. 2019). Recently, important clinical findings indicated that peripheral blood S100B levels can rule out central nervous system damage which was measured by magnetic resonance imaging in patients (Moss et al. 2020; Thompson et al. 2016). Therefore, scientists assume that peripheral blood S100B levels may reflect the presence of neuropathological conditions (Hughes et al. 2018; Shotar et al. 2019). The measurement of S100B in peripheral blood is much easier than the direct evaluation of S100B in the brain, and S100B levels in peripheral blood may have potential as a useful biomarker for ASD.
The view that “the periphery is a window to the brain” prompted scientists to evaluate the correlation between peripheral blood S100B levels and ASD. But the correlation is still uncertain. Some studies have shown that individuals with ASD had higher peripheral blood S100B levels than healthy controls (Al-Ayadhi and Mostafa 2012; Guloksuz et al. 2017). Other studies have found that there is no correlation between peripheral blood S100B levels and ASD (Esnafoglu et al. 2017; Ma et al. 2019).
Thus, a meta-analysis on this topic is necessary. In this study, we systematically reviewed studies investigating the correlation between peripheral blood S100B levels and ASD. Then, subgroup and meta-regression analyses were carried out to estimate heterogeneity.
Methods
Literature Search
A search for relevant studies published before May 5, 2020 in the Embase, Scopus, PubMed, Cochrane Library, Web of Science, Wanfang, and China National Knowledge Infrastructure databases was performed. The terms applied for the database search included “autism spectrum disorder,” “ASD,” “autism,” “pervasive developmental disorder,” “Asperger syndrome,” “autistic disorder,” “S100B,” “S100 calcium-binding protein β subunit,” “S100b,” “S100β,” “S100B protein,” and “S100 calcium binding protein beta subunit.” Studies in humans and published in either the English language or the Chinese language were adopted.
Study Selection
Inclusion criteria were (1) an evaluation of peripheral blood S100B levels in individuals with ASD and (2) a description of S100B levels in the median and range, the mean and standard deviation (SD), or the mean and standard error of the mean (SEM).
Exclusion criteria were (1) animal studies, reviews, abstracts, and letters; (2) study populations duplicated in another study; (3) studies that did not measure peripheral blood S100B levels, including pharmacology, genetics, brain imaging, and postmortem studies; and (4) studies that showed peripheral blood S100B levels in dot plot or histogram format, with no numerical results provided.
Data Extraction
Data on the author, number of samples, number of males, participant age and publication year were extracted. Data on country, ASD diagnostic criteria, adjusted confounders, study design, analytical technology, biomaterial, S100B and measurement unit were also extracted. Different measurement units (ng/ml, pg/ml, or ug/l) were used in the studies. All S100B levels were reported in pg/ml in this meta-analysis. If data were expressed in terms of the median and range, the sample mean and SD were calculated according to the method of Wan et al. (Wan et al. 2014). If data were presented with the SEM, then the sample SD was calculated using the formula SD = SEM x √n (n: sample size).
Quality Evaluation
The quality of the studies was estimated by the Newcastle–Ottawa Scale (NOS) (Stang 2010). The studies were evaluated as high (scored 7–9), medium (scored 4–6), or low (scored 0–3) quality.
Statistical Analysis
The standard mean difference (SMD) was summarized to calculate peripheral blood S100B levels in ASD. Heterogeneity was determined by the I2 and Q statistics. The I2 values of 0.25, 0.5, and 0.75 revealed small, medium and high heterogeneity, respectively.
Publication bias was confirmed by funnel plot analysis as well as by Begg’s and Egger’s tests. Subgroup analyses were carried out by using study design, biomaterial, analytical technology, and geographic location. Meta-regressions were conducted to evaluate whether sample size, mean age, publication year, and gender affected the outcome. Sensitivity analysis was carried out by the omission of studies one by one to evaluate whether any study changed the overall outcome. Stata 12.0 and Review Manager 5.1.2 software were used to perform the statistical tests.
Results
Literature Search
We first conducted a systematic search and identified 16 studies from PubMed, 29 studies from Embase, two studies from the Cochrane Library, 38 studies from Scopus, 26 studies from the Web of Science, 16 studies from China National Knowledge Infrastructure, nine studies from the Wanfang database, and two additional studies from the scanning of references. After reviewing titles and abstracts, 13 papers on peripheral blood S100B levels in ASD were selected for full-text review. Subsequently, one study was excluded due to its irrelevant topic. One report without sufficient data was excluded. One report was excluded for not being published in English. Eventually, 10 studies with 822 participants and 451 cases met the criteria for inclusion in the present meta-analysis (Fig. 1).
Fig. 1
Flow-chart of study selection
×
Study Characteristics
The included studies were published from 2012 to 2019 (Abou-Donia et al. 2019; Al-Ayadhi and Mostafa 2012; Ayaydin and Kirmit 2020; Esnafoglu et al. 2017; Guloksuz et al. 2017; Ma et al. 2019; Peng and Zhu 2017; Shaker et al. 2016; Tomova et al. 2019; Zhou 2015) (Table 1). Ten studies encompassed 822 participants and 451 cases. Three studies were performed in China (Ma et al. 2019; Peng and Zhu 2017; Zhou 2015), three in Turkey (Ayaydin and Kirmit 2020; Esnafoglu et al. 2017; Guloksuz et al. 2017), one in the USA (Abou-Donia et al. 2019), one in Saudi Arabia (Al-Ayadhi and Mostafa 2012), one in Egypt (Shaker et al. 2016), and one in the Slovak Republic (Tomova et al. 2019). The sample sizes ranged from 10 (Abou-Donia et al. 2019) to 89 (Tomova et al. 2019). The mean age of participants varied from 1.8 (Peng and Zhu 2017) to 18 (Abou-Donia et al. 2019) years old. The mean S100B values of cases ranged from 0.36 ± 0.19 pg/ml (Abou-Donia et al. 2019) to 298,630 ± 161,140 pg/ml (Ma et al. 2019). Two different biomaterials for S100B assays were used in this systematic review: serum (Abou-Donia et al. 2019; Al-Ayadhi and Mostafa 2012; Ayaydin and Kirmit 2020; Esnafoglu et al. 2017; Ma et al. 2019; Peng and Zhu 2017; Shake 2016; Zhou 2015) and plasma (Guloksuz et al. 2017; Tomova et al. 2019). Moreover, 9 studies performed S100B assessment using enzyme linked immunosorbent assay (ELISA) (Al-Ayadhi and Mostafa 2012; Ayaydin and Kirmit 2020; Esnafoglu et al. 2017; Guloksuz et al. 2017; Ma et al. 2019; Peng and Zhu 2017; Shaker et al. 2016; Tomova et al. 2019; Zhou 2015) as an analytical procedure, whereas 1 adopted Western blot (WB) (Abou-Donia et al. 2019). In addition, ten studies considered gender and age as adjusted confounders (Abou-Donia et al. 2019; Al-Ayadhi and Mostafa 2012; Ayaydin and Kirmit 2020; Esnafoglu et al. 2017; Guloksuz et al. 2017; Ma et al. 2019; Peng and Zhu 2017; Shaker et al. 2016; Tomova et al. 2019; Zhou 2015). Two studies considered body mass index (BMI) as adjusted confounder (Esnafoglu et al, 2017; Guloksuz et al, 2017). One study considered socioeconomic status as adjusted confounder (Shaker et al. 2016).
Table 1
Characteristics of the studies
First author, year
Country
Study design
Sample sizes
ASD/controls
Male (n)
ASD/controls
Age Mean ± SD(range)
ASD/controls
ASD diagnostic criteria
Analytical technology
Biomaterial
S100B Mean ± SD ASD/controls
Unit of measure
Adjusted confounders
Abou-Donia MB,2019
USA
Cross-sectional
10/10
2/2
3–18
6–12
ADIR、ADOS、DSM-V
WB
Serum
0.36 ± 0.19
0.20 ± 0.13
None
Gender, age
Al-Ayadhi LY,2012
Saudi Arabia
Cross-sectional
64/46
50/34
8.4 ± 2.5
9.1 ± 2.4
DSM-IV
ELISA
Serum
207.97 ± 52.6
171.33 ± 34.65
pg/ml
Gender, age
Ayaydin H,2020
Turkey
Cross-sectional
43/41
30/31
6 ± 2.2
7 ± 2.2
DSM-IV
ELISA
Serum
49.13 ± 1.57
24.33 ± 24.2
pg/ml
Gender, age
Esnafoglu E,2017
Turkey
Cross-sectional
35/31
26/25
7.6 ± 3.62
6.85 ± 3.16
DSM-V
ELISA
Serum
3.33 ± 4.19
3.42 ± 4.56
pg/ml
Gender, age, BMI
Guloksuz SA,2017
Turkey
Cross-sectional
40/35
30/22
7.13 ± 3.89
6.75 ± 3.96
DSM-IV
ELISA
Plasma
182.50 ± 34.61
48.13 ± 13.17
pg/ml
Gender, age, BMI
Ma F,2019
China
Cross-sectional
35/40
22/25
4.3 ± 0.5
4.4 ± 0.6
DSM-V
ELISA
Serum
298,630 ± 161,140
272,440 ± 122,280
pg/ml
Gender, age
Peng ZQ,2017
China
Cross-sectional
65/72
53/61
1.8–9.5
2.1–9.4
DSM-IV
ELISA
Serum
296,700 ± 154,690
244,390 ± 154,060
pg/ml
Gender, age
Shaker NM,2016
Egypt
Case–control
30/22
27/20
3–14
3–13
ICD-10
ELISA
Serum
123.8 ± 123.4
112.8 ± 9.3
pg/ml
Gender, age, socioeconomic status
Tomova A,2019
Slovak Republic
Cross-sectional
89/34
89/34
2–16
2–12
DSM-V、ADOS-2、ADIR
ELISA
Plasma
33.04 ± 31.6
23.26 ± 16.7
pg/ml
Gender, age
Zhou YY,2015
China
Cross-sectional
40/40
32/30
2–5
2–5
ABC
ELISA
Serum
195.43 ± 41.62
151.88 ± 21.06
pg/ml
Gender, age
To identify ASD cases, researchers adopted the diagnostic criteria from the Autism Diagnostic Interview-Revised (ADI-R) (Abou-Donia et al. 2019; Tomova et al. 2019), Diagnostic and Statistical Manual (DSM-IV) (Al-Ayadhi and Mostafa 2012; Ayaydin and Kirmit 2020; Guloksuz et al. 2017; Peng and Zhu 2017), DSM-V (Abou-Donia et al. 2019; Esnafoglu et al. 2017; Ma et al. 2019; Tomova et al. 2019), Autism Diagnostic Observation Schedule (ADOS) (Abou-Donia et al. 2019), ADOS-2 (Tomova et al. 2019), Autism Behavior Checklist (ABC) (Zhou 2015), and International Classification of Diseases, 10th Revision (ICD-10) (Shaker et al. 2016).
Main Correlation of Peripheral Blood S100B Levels with ASD
The results showed that individuals with ASD had higher peripheral blood S100B levels than healthy controls [SMD = 0.97, 95% confidence interval (95% CI) = 0.41–1.53; p < 0.001] but with significant heterogeneity (I2 = 93%, p < 0.001) (Fig. 2).
Fig. 2
Forest plot of the relative peripheral blood S100B levels in individuals with ASD
×
Quality Evaluation
The quality evaluation results showed that the ten studies were high quality. The mean score was 7.7 (Table 2).
Asymmetry was found by funnel plot analysis (Fig. 3). Begg’s and Egger’s tests demonstrated no obvious publication bias (Begg’s test, p = 0.37; Egger’s test, p = 0.07).
Fig. 3
Funnel plot of the relative peripheral blood S100B levels in individuals with ASD
×
Subgroup Analysis
We performed subgroup analysis based on study design. The pooled SMDs were 1.07 (95% CI = 0.46–1.68, p < 0.001) for cross-sectional studies and 0.12 (95% CI = −0.44–0.67, p = 0.68) for case–control study. Further subgroup analysis of biomaterials showed that individuals with ASD had higher peripheral blood S100B levels in serum [0.62 (95% CI = 0.24–1.01, p = 0.002)] but not in plasma [2.63 (95% CI = −1.89–7.15, p = 0.25)]. In addition, we conducted subgroup analysis on the basis of which analysis techniques were applied. The effect values of S100B levels in individuals with ASD were 0.94 (95% CI = 0.01–1.88, p = 0.05) for WB and 0.97 (95% CI = 0.37–1.57, p = 0.001) for ELISA. We also carried out subgroup analysis in terms of geographic locations. The results demonstrated that individuals with ASD had higher peripheral blood S100B levels in other countries [0.5 (95% CI = 0.16–0.85, p = 0.004)] but not in China [0.6 (95% CI =−0.03–1.23, p = 0.06)] or Turkey [2.09 (95% CI = −0.16–4.34, p = 0.07)] (Table 3).
Table 3
Stratified analysis of peripheral blood S100B levels in individuals with ASD
Variables
No. of comparisions
No. of subjects
Meta-analysis
Heterogeneity
Test for subgroup differences
ASD
Controls
SMD
95%CI
p-value
I2
p-value
I2
p-value
Study design
Case–control
1
30
22
0.12
−0.44
0.67
0.68
Not applicable
Not applicable
80.6
0.02
Cross-sectional
9
421
349
1.07
0.46
1.68
< 0.001
93
< 0.001
Biomaterial
Plasma
2
129
69
2.63
−1.89
7.15
0.25
99
< 0.001
0
0.39
Serum
8
322
302
0.62
0.24
1.01
0.002
81
< 0.001
Analytical technology
WB
1
10
10
0.94
0.01
1.88
0.05
Not applicable
Not applicable
0
0.95
ELISA
9
441
361
0.97
0.37
1.57
0.001
93
< 0.001
Geographic location
China
3
140
152
0.6
−0.03
1.23
0.06
85
0.001
0
0.39
Turkey
3
118
107
2.09
−0.16
4.34
0.07
98
< 0.001
Others
4
193
112
0.5
0.16
0.85
0.004
45
0.14
No. number, CI confidence interval.
Meta-Regression Analysis
The meta-regression analyses indicated that none of the covariates (sample size, mean age, publication year, and gender) significantly influenced the results (Table 4).
Table 4
Meta-regression of peripheral blood S100B levels in individuals with ASD
Moderator
No. of comparisions
No. of subjects
Meta-regression
Proportion of
variance explained
ASD
Controls
Slope
95%CI
p-value
R2 analog
Age(mean, years)
10
451
371
0.77
−1.58
3.15
0.47
−5.76
Gender(%man)
10
451
371
−0.52
−0.07
0.04
0.62
−9.38
Sample size
10
451
371
−0.3
−0.04
0.029
0.77
−12.83
Publication year
10
451
371
−0.03
−0.5
0.49
0.98
−14.66
No. number, CI confidence interval.
Sensitivity Analysis
Sensitivity analysis revealed that the overall results were not affected by a particular study.
Discussion
To our knowledge, this is the first meta-analysis to explore peripheral blood S100B levels in ASD. Pooling the ten studies, 822 participants and 451 cases were encompassed. Our study showed that individuals with ASD had higher peripheral blood S100B levels than healthy controls. Sensitivity analysis indicated that the outcome was not unduly influenced by a particular study. In addition, no obvious publication bias was observed. This study demonstrated that individuals with ASD had higher peripheral blood S100B levels.
High levels of heterogeneity were detected in this study. Subgroup analyses revealed that different study designs contributed to the heterogeneity. Individuals with ASD who had higher peripheral blood S100B levels were detected in cross-sectional studies but not in case–control study, indicating that the association may be affected by the study design. But this analysis may have been underpowered owing to only one case–control study was included in the subgroup. This potential confounding factor needs to be considered in the future analysis of S100B in individuals with ASD.
Individuals with ASD had higher S100B levels when measured in serum but not when measured in plasma. In the meta-analysis, most studies provided serum S100B levels; therefore, enough data were available to conclude that ASD is correlated with elevated serum S100B levels. Evidence that changes in serum S100B levels may reflect changes occurring in the brain has been reported (Vos et al. 2010). In some central nervous system disorders, such as intracerebral haemorrhage and ischaemia–reperfusion injury, the increase in serum S100B levels was consistently detected by biochemical analyses of S100B levels in the brain (Liu et al. 2015; Neves et al. 2017). Furthermore, serum S100B levels have been used as a standard indicator of treatment response in cerebral ischaemia–reperfusion injury (Li and Liu 2017). Therefore, in our meta-analysis, elevated serum S100B levels in individuals with ASD may reflect what is happening in the brains of individuals with ASD. Few studies have analyzed plasma S100B levels. It is necessary to further study the plasma S100B levels in this population.
Interestingly, the peripheral blood S100B levels were higher in individuals with ASD than in healthy controls when measured by ELISA but not when measured by WB, indicating that different assay methods may affect the correlation. Assay properties such as sensitivity and inter-assay and intra-assay coefficients of variability should be considered. In addition, differences in the way samples are collected and handled might contribute to the discrepancies in reported S100B levels in individuals with ASD. But only one study utilized WB in the subgroup, the result was not robust. Further investigations are needed to explore the correlation between S100B levels measured by WB and ASD.
In addition, individuals with ASD were discovered to have higher peripheral blood S100B levels than healthy controls in other countries, but there was no difference between the groups in China or Turkey. Genetic factors, environmental factors, lifestyle and economic conditions may contribute to this difference.
Furthermore, some clinical confounders were not analyzed in our meta-analysis, such as BMI, leptin and other adipose-related factors, may contribute to the observed heterogeneity. Scientists have reported that S100B levels were closely correlated with BMI, leptin and other adipose-related factors (Steiner et al. 2010). The studies included in our meta-analysis did not report BMI, leptin and other adipose-related factors, which made it impossible to analyze whether they were confounders contributed to the heterogeneity. It raises awareness of the need to consider these factors in future works.
The mechanisms of increased S100B in ASD are not completely clear, but several mechanisms have been proposed. First, autoimmunity may be involved in the development of ASD (Edmiston et al. 2017). Brain-specific autoantibodies have been found in individuals with ASD (Ramirez-Celis et al. 2020). Autoantibodies can bind to brain tissue antigens by passing through the blood–brain barrier, forming immune complexes and leading to neuronal damage (Al-Ayadhi and Mostafa 2012). Elevated S100B levels may indicate neuronal damage in ASD. Second, neuroinflammation was found in the brains of individuals with ASD (Matta et al. 2019). It has been reported that S100B may modulate cytokine secretion and may also be modulated by pro-inflammatory cytokines (Di Sante et al. 2020). S100B may function as a cytokine and support the implication of neuroinflammation in the development of ASD (Shaker NM 2016). Third, S100B has both trophic and toxic effects on neurons, depending on its concentration. When S100B levels are excessively increased, S100B acts as a neurotoxic protein that induces apoptosis. Ayaydın H et al. (Ayaydin and Kirmit 2020) reported that S100B plays an important role in neuronal apoptosis, which may contribute to the pathogenesis of ASD. The pathophysiological roles of S100B in ASD are not well explained, and more studies are warranted to verify this assumption in the future.
This meta-analysis had the following strengths. First, this is the first meta-analysis carried out to evaluate peripheral blood S100B levels in ASD. Second, no significant publication bias existed, indicating the high reliability of the results. Third, the sensitivity analysis found that no study could change the outcome, demonstrating that the conclusion was robust.
However, there were some limitations. First, because of the small sample size, studies with larger samples are required to illustrate the role of peripheral blood S100B levels in ASD. Second, since only a few studies analyzed the severity of ASD and S100B levels, the correlation between them was not evaluated. Future studies should pay attention to this subject. Third, the meta-analysis provides us with comprehensive results mainly from cross-sectional studies. Therefore, whether S100B levels are the cause or the result of ASD development remains unclear. Fourth, significant heterogeneity was found in this meta-analysis. Random-effects, subgroup and regression analyses were performed, and different study designs explained the heterogeneity. But residual confounding factors such as a wide range of mean S100B values reported across studies, which may be related with the different measurement units and different analytical technologies used in the included studies, are still a problem worthy of attention. Therefore, heterogeneity may influence the accuracy of the final results.
Despite these limitations, this study may have clinical application value for using S100B levels in the early identification and evaluation of ASD progression. This meta-analysis provides clinical evidence that individuals with ASD have increased peripheral blood S100B levels. Scientists have reported that changes in peripheral blood S100B levels may reflect changes occurring in the brain (Vos et al. 2010). Thus, higher peripheral blood S100B levels may reveal higher brain S100B levels in individuals with ASD. Brain S100B levels in individuals with ASD are warranted to be evaluated to confirm this hypothesis, which may further support that S100B can be used as a reliable biomarker for ASD.
Conclusions
This analysis provides evidence that individuals with ASD have increased peripheral blood S100B levels. Peripheral blood S100B levels may have potential as a useful biomarker for ASD. Studies with large samples are warranted to investigate the severity of the clinical symptoms and the causal relationship between ASD and S100B levels.
Acknowledgements
This work was funded by the National Science Foundation of China (81901523, 81873801) and a Grant from the Fundamental Research Funds for the Central Universities (19ykpy38).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Met BSL Psychologie Totaal blijf je als professional steeds op de hoogte van de nieuwste ontwikkelingen binnen jouw vak. Met het online abonnement heb je toegang tot een groot aantal boeken, protocollen, vaktijdschriften en e-learnings op het gebied van psychologie en psychiatrie. Zo kun je op je gemak en wanneer het jou het beste uitkomt verdiepen in jouw vakgebied.
